These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30083378)

  • 1. Alprazolam-induced dose-dependent anorgasmia: case analysis.
    Kaufman KR; Coluccio M; Linke M; Noonan E; Babalola R; Aziz R
    BJPsych Open; 2018 Jul; 4(4):274-277. PubMed ID: 30083378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review.
    Kaufman KR; Coluccio M; Sivaraaman K; Campeas M
    BJPsych Open; 2017 Sep; 3(5):249-253. PubMed ID: 29034101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder.
    Ciraulo DA; Barnhill JG; Boxenbaum HG; Greenblatt DJ; Smith RB
    J Clin Pharmacol; 1986 Apr; 26(4):292-8. PubMed ID: 2871050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gabapentin-induced sexual dysfunction.
    Kaufman KR; Struck PJ
    Epilepsy Behav; 2011 Jul; 21(3):324-6. PubMed ID: 21612983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sexual problems in the patients with psychiatric disorders.
    Piontek A; Szeja J; Błachut M; Badura-Brzoza K
    Wiad Lek; 2019 Oct; 72(10):1984-1988. PubMed ID: 31982027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panic disorder: long-term pharmacotherapy and discontinuation.
    Rickels K; Schweizer E
    J Clin Psychopharmacol; 1998 Dec; 18(6 Suppl 2):12S-18S. PubMed ID: 9872708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of chronic use of alprazolam and lorazepam.
    Romach M; Busto U; Somer G; Kaplan HL; Sellers E
    Am J Psychiatry; 1995 Aug; 152(8):1161-7. PubMed ID: 7625464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alprazolam as treatment for a case of obsessive-compulsive disorder.
    Tesar GE; Jenike MA
    Am J Psychiatry; 1984 May; 141(5):689-90. PubMed ID: 6143507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment.
    Sheehan DV; Coleman JH; Greenblatt DJ; Jones KJ; Levine PH; Orsulak PJ; Peterson M; Schildkraut JJ; Uzogara E; Watkins D
    J Clin Psychopharmacol; 1984 Apr; 4(2):66-75. PubMed ID: 6142907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-potency benzodiazepines: recent clinical results.
    Moroz G
    J Clin Psychiatry; 2004; 65 Suppl 5():13-8. PubMed ID: 15078113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.
    Pecknold JC; Swinson RP; Kuch K; Lewis CP
    Arch Gen Psychiatry; 1988 May; 45(5):429-36. PubMed ID: 3282479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.
    Nagy LM; Krystal JH; Woods SW; Charney DS
    Arch Gen Psychiatry; 1989 Nov; 46(11):993-9. PubMed ID: 2818144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
    Moylan S; Staples J; Ward SA; Rogerson J; Stein DJ; Berk M
    J Clin Psychopharmacol; 2011 Oct; 31(5):647-52. PubMed ID: 21869686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study.
    O'Sullivan GH; Swinson R; Kuch K; Marks IM; Basoglu M; Noshirvani H
    J Psychopharmacol; 1996 Jan; 10(2):101-9. PubMed ID: 22302886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of panic disorder to fixed doses of alprazolam or imipramine.
    Uhlenhuth EH; Matuzas W; Glass RM; Easton C
    J Affect Disord; 1989; 17(3):261-70. PubMed ID: 2529295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.